立方制药(003020) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥360,228,684.63, representing a 7.98% increase compared to ¥333,618,253.50 in the same period last year[3] - Net profit attributable to shareholders was ¥38,250,279.27, a 25.94% increase from ¥30,372,220.01 year-on-year[3] - Basic and diluted earnings per share rose to ¥0.20, reflecting a 25.00% increase from ¥0.16 in the same period last year[3] - Operating profit for the current period was ¥44,108,590.09, compared to ¥29,015,119.09 in the previous period, indicating a significant increase of 52.1%[26] - Net profit for the current period was ¥39,275,579.73, a 43.0% increase from ¥27,455,521.45 in the previous period[26] - Total comprehensive income for the period reached ¥39,275,579.73, up from ¥27,455,521.45 in the previous period, representing a growth of approximately 43.1%[27] Cash Flow - The net cash flow from operating activities increased by 132.91% to ¥36,061,213.31, up from ¥15,482,874.04 in the previous year[3] - Cash inflow from operating activities totaled ¥430,690,872.38, an increase from ¥381,665,137.63, reflecting a growth of approximately 12.8%[27] - Cash flow from investing activities showed a net outflow of ¥19,028,476.88, an improvement from a net outflow of ¥328,421,286.75 in the previous period[28] - The company’s net cash increase for the period was -¥25,407,114.22, a significant improvement from -¥315,371,864.11 in the prior period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,596,058,497.33, a slight increase of 0.39% from ¥2,585,975,314.11 at the end of the previous year[3] - Total liabilities decreased to ¥644,354,707.70 from ¥673,376,707.67, a reduction of 4.3%[23] - The company's equity attributable to shareholders increased by 2.19% to ¥1,775,966,833.09 from ¥1,737,886,950.36 at the end of the previous year[3] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,706, with the largest shareholder holding 27.09% of the shares[12] - The company completed the repurchase and cancellation of 311,263 restricted shares, reducing total share capital from 191,571,763 shares to 191,260,500 shares, representing a 0.16% decrease[16] - The company distributed cash dividends of RMB 2 per 10 shares, totaling RMB 38,252,100 (including tax) based on a total share capital of 191,260,500 shares[16] Research and Development - Research and development expenses for the current period were ¥19,080,113.30, down from ¥23,546,764.47, a decrease of 18.9%[26] - The company was awarded the "High-tech Enterprise Certificate," valid for three years, enhancing its innovation capabilities[17] - The company signed an agreement with Hefei Cube Investment Group to cultivate innovative drug research projects, ensuring priority manufacturing rights for successful products[18] Other Income and Expenses - The company received government subsidies amounting to ¥7,529,093.45, contributing to the increase in other income by 427.78%[4][9] - The company reported a significant decrease in financial expenses by 48.85% to -¥22.56, primarily due to reduced interest income from deposits[9] Current Assets - The company’s total current assets as of March 31, 2025, amounted to RMB 1,193,930,238.63, showing a slight increase from RMB 1,185,494,963.22 at the beginning of the period[21] - The company’s accounts receivable increased to RMB 403,172,219.46 from RMB 369,023,105.03, reflecting a growth of approximately 9.2%[21] - The company’s inventory as of March 31, 2025, was RMB 233,749,768.41, up from RMB 220,484,038.25, indicating an increase of about 6.3%[21] - The company’s long-term equity investments rose to RMB 176,967,615.55 from RMB 174,675,297.68, marking an increase of approximately 1.3%[21] - The company’s fixed assets decreased to RMB 678,069,352.10 from RMB 692,904,360.14, representing a decline of about 2.1%[21]